Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An existing malaria rapid diagnostic test (RDT) can be adapted to predict the delayed anaemia that can complicate severe malaria in patients treated with artemisinin-based antimalarial drugs

Researcher checking a child affected with malaria for anaemia

“These findings are relevant to the thousands of western travellers treated each year for malaria and for non-immune adults in low malaria transmission places like Bangladesh, Thailand and Myanmar,” said Dr Charlie Woodrow, one of the study’s lead authors, based at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand.

“Using a modified rapid test – a dipstick, if you will – physicians can predict who is at high risk of delayed anaemia and anticipate the need for hospital admission and blood transfusion,” explained Dr Woodrow. “Patients identified as being low risk, on the other hand, can be reassured and told to come back only if their symptoms worsen.”

Artesunate, the most commonly used artemisinin for severe malaria, rapidly cures patients with severe malaria but frequently induces anaemic episodes called post-artesunate delayed hemolysis (PADH) for which a simple predictive method has been needed.

The researchers, based in France, Thailand and Bangladesh, found that the underlying event in PADH, the expulsion of artesunate-exposed parasites from their host red blood cells by “pitting”,  leaves behind the parasite component PfHRP2 in the red cell. So using a dipstick to measure the amount of PfHRP2 in the blood just after parasite clearance indicates the number of "deparasitized" red cells – and the risk of life-threatening anaemia.

The finding that PfHRP2 persists in deparasitized red cells also solves a long-standing mystery – why the rapid diagnostic test for falciparum malaria stays positive for so long after treatment.

“Our work hence joins together three separate strands of study – the process of pitting, the persistence of PfHRP2 after treatment and the risk of delayed haemolysis after artesunate,” said Dr Woodrow.

Led by researchers at the National Institute of Blood Transfusion, Paris Descartes University with support from, among others, scientists at the Mahidol Oxford Tropical Medicine Research Unit (MORU) at Mahidol University, Bangkok, Thailand and the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, the study was funded by the French National Research Agency, the Wellcome Trust (UK) and the Bill and Melinda Gates Foundation.

Study Reference:

Persistence of the Plasmodium falciparum protein HRP2 in the circulation of artesunate-treated malaria patients predicts post-artesunate hemolysis.Ndour PA, Larréché S, Mouri O, Argy N, Gay F, Roussel C, Jauréguiberry S, Perillaud C, Langui D, Biligui S, Chartrel N, Mérens A,  Kendjo E, Ghose A, Hassan MMU, Hossain MA, Kingston HWF, Plewes K, Dondorp AM, Danis M, Houzé S,  Bonnefoy S, Thellier M, Woodrow CJ, Buffet PA,  French Artesunate Working Group. Sci Transl Med. 2017 Jul 5;9(397). pii: eaaf9377. doi: 10.1126/scitranslmed.aaf9377.

Similar stories

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.